Information Regarding Clinical Trial

Title	A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or second line therapy in patients with advanced triple-negative breast cancer
Protocol Number	CLAG525B2101
Sponsor	Novartis
Investigator	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
Study Related Phone Numbers	479-587-1700 (24 hours)
Key Points for Study	- Current measurable dz - Required new bx at screening unless no anti-cancer tx since archival bx - Progression after adjuvant or 1 prior systemic tx in metastatic setting - Must have prior systemic tx with taxane-based chemo for adjuvant or metastatic dz - No prior tx with immune-checkpoint inhibitor - No recurrence within 12 months after end of platinum-based or mitomycin therapy - No hx acute pancreatitis within 1 year or hx chronic pancreatitis - No hx CNS mets, Stevens-Johnson syndrome, interstitial lung dz or pneumonitis